Physician Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bolder BioTechnology, Inc.
U.S. NIH grant will help develop infection fighting protein
June 15th, 2005
Bolder BioTechnology, Inc., announced that it has been awarded a $99,000 phase I Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the U.S. National Institutes of Health. The grant supports research to improve the pharmacological properties of a human protein, gamma interferon, to enhance its ability to stimulate the body's immune system to fight infections. The optimized gamma interferon protein may prove useful for the treatment of viral infections, immunodeficiencies and various cancers. The SBIR program is a peer-reviewed grant program that provides research support to small...
Source: Physician Law Weekly (2005-06-15)
|
